Search
Search titles only
By:
Search titles only
By:
Home
Forums
New posts
Search forums
What's new
New posts
New profile posts
Latest activity
Members
Current visitors
New profile posts
Search profile posts
Log in
Register
Search
Search titles only
By:
Search titles only
By:
New posts
Search forums
Menu
Install the app
Install
Reply to Thread
Guest, we'd love to know what you think about the forum! Take the
Diabetes Forum Survey 2024 »
Home
Forums
Diabetes News and Research
Diabetes News
CGM device returns 93 per cent accuracy in type 1 and type 2 diabetes trial
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Message
<blockquote data-quote="DCUK NewsBot" data-source="post: 1698337" data-attributes="member: 106455"><p>A continuous glucose monitoring (CGM) device has shown to be safe and highly accurate in people with type 1 diabetes and type 2 diabetes. The Eversense CGM system demonstrated more than 93% accuracy of glucose readings from 90 participants with diabetes in a new trial. The system includes an implantable sensor which lasts for 90 days and measures glucose levels from interstitial fluid below the skin surface. The Eversense CGM was assessed as part of the PRECISE II study, with researchers primarily monitoring how glucose readings compared to reference values within similar ranges. The CGM's high accuracy was complemented by its favourable safety profile, measured by how easily and successfully the device could be inserted and removed, and how many procedure-related adverse events occurred. The results showed that clinicians with limited to no surgical experience could safely insert and remove the CGM following training. Only one serious adverse event was reported due to sensor insertion or removal. Due to the CGM's 93% accuracy and overall safety, Satish Garg, MD, editor-in-chief of Diabetes Technology &Therapeutics, the journal in which the results appear, believes there should be increased optimism regarding the future of CGMs. "Continuous glucose monitoring is becoming standard of care especially for insulin-requiring patients with diabetes," said Dr Garg. "Eversense, if approved by the FDA, will become the first implantable CGM system for use lasting at least three months." First author Mark Christiansen, MD, Leslie Klaff, MD, and colleagues added: "The results from this study demonstrate that the use of a long-term, 90-day, implantable continuous glucose sensor is accurate and safe with high rates of adherence to use. "Additional clinical studies will be required to evaluate the accuracy and usability of the Eversense CGM system among pediatrics, with reduced calibration frequency, and for extended durations through 180 days."</p><p></p><p><a href="http://www.diabetes.co.uk/news/2018/feb/cgm-device-returns-93-per-cent-accuracy-in-type-1-and-type-2-diabetes-trial-94074681.html" target="_blank">Continue reading...</a></p></blockquote><p></p>
[QUOTE="DCUK NewsBot, post: 1698337, member: 106455"] A continuous glucose monitoring (CGM) device has shown to be safe and highly accurate in people with type 1 diabetes and type 2 diabetes. The Eversense CGM system demonstrated more than 93% accuracy of glucose readings from 90 participants with diabetes in a new trial. The system includes an implantable sensor which lasts for 90 days and measures glucose levels from interstitial fluid below the skin surface. The Eversense CGM was assessed as part of the PRECISE II study, with researchers primarily monitoring how glucose readings compared to reference values within similar ranges. The CGM's high accuracy was complemented by its favourable safety profile, measured by how easily and successfully the device could be inserted and removed, and how many procedure-related adverse events occurred. The results showed that clinicians with limited to no surgical experience could safely insert and remove the CGM following training. Only one serious adverse event was reported due to sensor insertion or removal. Due to the CGM's 93% accuracy and overall safety, Satish Garg, MD, editor-in-chief of Diabetes Technology &Therapeutics, the journal in which the results appear, believes there should be increased optimism regarding the future of CGMs. "Continuous glucose monitoring is becoming standard of care especially for insulin-requiring patients with diabetes," said Dr Garg. "Eversense, if approved by the FDA, will become the first implantable CGM system for use lasting at least three months." First author Mark Christiansen, MD, Leslie Klaff, MD, and colleagues added: "The results from this study demonstrate that the use of a long-term, 90-day, implantable continuous glucose sensor is accurate and safe with high rates of adherence to use. "Additional clinical studies will be required to evaluate the accuracy and usability of the Eversense CGM system among pediatrics, with reduced calibration frequency, and for extended durations through 180 days." [url="http://www.diabetes.co.uk/news/2018/feb/cgm-device-returns-93-per-cent-accuracy-in-type-1-and-type-2-diabetes-trial-94074681.html"]Continue reading...[/url] [/QUOTE]
Verification
Post Reply
Home
Forums
Diabetes News and Research
Diabetes News
CGM device returns 93 per cent accuracy in type 1 and type 2 diabetes trial
Top
Bottom
Find support, ask questions and share your experiences. Ad free.
Join the community »
This site uses cookies. By continuing to use this site, you are agreeing to our use of cookies.
Accept
Learn More.…